Pfizer CEO: Vaccine Could Be Ready In October But Won't Be Hurried By Political Pressure
Warp Speed Leader Doubts October Timeline
Executive Summary
Bourla reassures on scientific integrity amid fears of a politically motivated Emergency Use Authorization.
You may also be interested in...
Pfizer Appears Slightly Ahead Of Moderna In COVID-19 Vaccine Race
Neither has announced a firm timeline, and the difference between Pfizer's 'October' and Moderna's 'November' could be mere hours or a few weeks, but Pfizer, by dint of luck or experience, is now in a position to offer the more optimistic projection on when it will seek an EUA. Both firms release their Phase III trial protocols, which seem in line with US FDA guidance.
Takeda Vaccines Head: Peer Review Process For COVID-19 Vaccines Must Be 'Very Open'
The president of Takeda’s global vaccines business emphasizes the need to build trust and ensure that pharma is transparent about “what we will and will not know” at the time that COVID-19 vaccines are licensed.
COVID-19 Vaccine Sponsors’ Pledge To Wait For Phase III Helps US FDA
The move reduces the pressure on the companies to rush development, but also relieves burden on the FDA to approve a candidate too soon.